POZ - Latino Hub : News : Baylor Health Care System Receives $8M to Research Drug-Free HIV Treatment

POZ Latino / Hispanic Hub
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
|
|
|
|
|
|
|
|
|
 

Back to home » News & Views » News


 

February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007


emailrssprint

June 18, 2009

Baylor Health Care System Receives $8M to Research Drug-Free HIV Treatment

The government of France has donated $8 million to the Texas-based Baylor Health Care System to develop a therapeutic way to manage HIV without drugs, the Dallas Morning News reports.

According to the article, the funding will be used to establish an HIV research component to Baylor’s Institute of Immunology Research. The money will go toward equipment, staff and clinical trials.

Jacque Banchereau, MD, Baylor’s director of immunology research, specializes in dendritic cells, which are the body’s first line of defense against disease and infection. Through his research, Banchereau is hoping to extract these cells from HIV-positive patients, manipulate them and then inject them back into the patients’ bodies to help control the virus without antiretroviral medication.

Banchereau has 10 northern Texas patients in Phase I of the trial, all of whom have lived with HIV for several years and have been on medication. The trial requires, however, that participants go off their medication during the testing.

“When you interrupt therapy, the virus comes back,” Banchereau said. “We hope that it comes back much slower. If we can do that, we hit a home run.” Baylor hopes primary trials go well enough to move on to Phase II of the clinical trial, which could include additional participants.

NEW! Scroll down to comment on this story.

emailrssprint

 

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

         


[Go to top]

Protesters hold the Hershey Company and its affiliated school accountable for condoning HIV-related discrimination. Click here to read more.
What to do if you've just been diagnosed
Qué hacer si eres recién diagnosticado

How to find a support system
Cómo encontrar un sistema de apoyo

Things you should know before starting treatment
Cosas que deberías saber antes de comenzar un tratamiento

How to handle side effects and other concerns
Cómo tratar los efectos secundarios y otros problemas de salud

How to tell someone you have HIV/AIDS
Cómo revelar tu diagnóstico de VIH/SIDA
[an error occurred while processing this directive]
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.